Macular Telangiectasia
Ace the Case: A 46-year-old woman with diagnosed HHT, an epistaxis severity score of 4.15/10, and iron deficiency anemia
This activity was supported by an independent, unrestricted educational grant from Pharmacosmos Therapeutics, Inc.
Ace the Case: A 61-year-old woman with HHT, severe ongoing epistaxis, evidence of gastrointestinal bleeding, and severe pain in her right hip
This activity was supported by an independent, unrestricted educational grant from Pharmacosmos Therapeutics, Inc.
Ace the Case: A 31-year-old man, with a history of frequent nosebleeds and iron deficiency, diagnosed with von Willebrand disease
This activity was supported by an independent, unrestricted educational grant from Pharmacosmos Therapeutics, Inc.
VIDEO: Neurotech prepares to launch Encelto for macular telangiectasia type 2
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Richard Small, CEO of Neurotech Pharmaceuticals, provides an update on Encelto for macular telangiectasia type 2.
Uveitic Macular Edema: Enhancing Visual Outcomes Through the Use of Corticosteroid Delivery Systems
This activity is supported by an educational grant from Bausch + Lomb.
Q&A: Altris AI launches AI-powered optic disc analysis
Altris AI, which offers OCT analysis for retinal diseases, is now expanding to glaucoma detection.
FDA approves Encelto for macular telangiectasia type 2
The FDA approved Encelto, an encapsulated cell therapy, for the treatment of macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.
Consider AMD mimics to avoid misdiagnosis, unnecessary treatment
ORLANDO — Ophthalmologists must take measures to avoid misdiagnosing age-related macular degeneration and consider mimics of the disease, according to a speaker at Telling It Like It Is.
VIDEO: Three trials reinforce positive results of MacTel treatment
KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, W. Lloyd Clark, MD, discusses positive results from three clinical trials investigating NT-501 for macular telangiectasia type 2.
VIDEO: NT-501 for macular telangiectasia nears PDUFA date
KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2025, Richard Small, CEO of Neurotech Pharmaceuticals, discusses the company’s macular telangiectasia therapy ahead of its upcoming Prescription Drug User Fee Act date.